CN1090170A - 以塔三烷衍生物为主组分的新组合物 - Google Patents

以塔三烷衍生物为主组分的新组合物 Download PDF

Info

Publication number
CN1090170A
CN1090170A CN93119653A CN93119653A CN1090170A CN 1090170 A CN1090170 A CN 1090170A CN 93119653 A CN93119653 A CN 93119653A CN 93119653 A CN93119653 A CN 93119653A CN 1090170 A CN1090170 A CN 1090170A
Authority
CN
China
Prior art keywords
composition according
solution
surfactant
additive
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93119653A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·鲍毕
P·戴兰狄
G·古伦
M·瓦拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9436137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1090170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of CN1090170A publication Critical patent/CN1090170A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Detergent Compositions (AREA)
CN93119653A 1992-12-02 1993-10-29 以塔三烷衍生物为主组分的新组合物 Pending CN1090170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9214501 1992-12-02
FR9214501A FR2698543B1 (fr) 1992-12-02 1992-12-02 Nouvelles compositions à base de taxoides.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN02147245.9 Division 1993-10-29

Publications (1)

Publication Number Publication Date
CN1090170A true CN1090170A (zh) 1994-08-03

Family

ID=9436137

Family Applications (2)

Application Number Title Priority Date Filing Date
CN93119653A Pending CN1090170A (zh) 1992-12-02 1993-10-29 以塔三烷衍生物为主组分的新组合物
CNB021472459A Ceased CN1291713C (zh) 1992-12-02 1993-10-29 以塔三烷衍生物为主组分的新组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021472459A Ceased CN1291713C (zh) 1992-12-02 1993-10-29 以塔三烷衍生物为主组分的新组合物

Country Status (28)

Country Link
US (1) US5438072A (cg-RX-API-DMAC7.html)
EP (1) EP0671912B1 (cg-RX-API-DMAC7.html)
JP (1) JP3689791B2 (cg-RX-API-DMAC7.html)
KR (1) KR100330316B1 (cg-RX-API-DMAC7.html)
CN (2) CN1090170A (cg-RX-API-DMAC7.html)
AT (1) ATE190838T1 (cg-RX-API-DMAC7.html)
AU (1) AU691476B2 (cg-RX-API-DMAC7.html)
CA (1) CA2150576C (cg-RX-API-DMAC7.html)
CZ (1) CZ284080B6 (cg-RX-API-DMAC7.html)
DE (2) DE69328192T4 (cg-RX-API-DMAC7.html)
DK (1) DK0671912T3 (cg-RX-API-DMAC7.html)
ES (1) ES2145115T4 (cg-RX-API-DMAC7.html)
FI (1) FI113619B (cg-RX-API-DMAC7.html)
FR (1) FR2698543B1 (cg-RX-API-DMAC7.html)
GE (1) GEP19991856B (cg-RX-API-DMAC7.html)
GR (1) GR3032828T3 (cg-RX-API-DMAC7.html)
HU (1) HU222833B1 (cg-RX-API-DMAC7.html)
MX (1) MX9306986A (cg-RX-API-DMAC7.html)
NO (1) NO314436B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ258150A (cg-RX-API-DMAC7.html)
PL (1) PL174334B1 (cg-RX-API-DMAC7.html)
PT (1) PT671912E (cg-RX-API-DMAC7.html)
RU (1) RU2144356C1 (cg-RX-API-DMAC7.html)
SK (1) SK281558B6 (cg-RX-API-DMAC7.html)
TW (1) TW271395B (cg-RX-API-DMAC7.html)
WO (1) WO1994012171A1 (cg-RX-API-DMAC7.html)
YU (1) YU49092B (cg-RX-API-DMAC7.html)
ZA (1) ZA938936B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3423317B2 (ja) 1993-07-19 2003-07-07 アンジオジェネシス テクノロジーズ インコーポレイテッド 抗−血管形成性組成物およびそれにより被覆されたステント
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
KR100191446B1 (ko) * 1996-05-02 1999-06-15 송영욱 파클리탁셀 함유 전신성 홍반성 낭창치료제
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
KR100330373B1 (ko) * 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
DE19655141C5 (de) 1996-11-08 2013-12-05 Eppendorf Ag Gradienten-Temperierblock für Laborthermostaten
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
IL132323A0 (en) * 1997-04-28 2001-03-19 Rhone Poulenc Rorer Sa Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
EP0998279B1 (en) * 1997-05-30 2002-10-16 Man Woo Han Pharmaceutical injection solution containing taxol
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
IL149488A0 (en) * 1999-11-15 2002-11-10 Pharma Mar Sa Pharmaceutical compositions containing aplidine
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
EP1435908A4 (en) * 2001-09-13 2006-03-15 Korea Inst Sci & Tech Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
NZ575452A (en) * 2002-05-24 2010-03-26 Angiotech Int Ag Compositions and methods for coating medical implants such as vascular grafts, catheters, pacemakers etc
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1534340B1 (en) 2002-09-06 2011-11-16 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2004293075A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
ES2410591T3 (es) * 2004-09-22 2013-07-02 Nippon Kayaku Kabushiki Kaisha Nuevo copolímero en bloque, preparación micelar y agente antineoplásico que lo contiene como principio activo
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2007111211A1 (ja) * 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
JP5181347B2 (ja) 2006-05-18 2013-04-10 日本化薬株式会社 ポドフィロトキシン類の高分子結合体
US20090239782A1 (en) * 2006-10-03 2009-09-24 Masaharu Nakamura High-molecular weight conjugate of resorcinol derivatives
JP5503872B2 (ja) 2006-11-06 2014-05-28 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
AU2008205330B2 (en) 2007-01-08 2014-07-03 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services SLCO1B3 genotype
CZ200756A3 (cs) * 2007-01-23 2008-07-30 Heaton, A. S. Dvousložková farmaceutická kompozice obsahující taxan
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2009007992A2 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical composition produced by microprecipitation
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
JP5349318B2 (ja) * 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101396354B (zh) * 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
CA2718233A1 (en) 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
DK2249825T3 (en) 2008-03-14 2016-01-11 Bionumerik Pharmaceuticals Inc Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US8920788B2 (en) * 2008-03-18 2014-12-30 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of physiologically active substances
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
RU2428175C2 (ru) * 2008-06-02 2011-09-10 Закрытое Акционерное Общество "Биокад" Способ получения парентерального фармацевтического раствора
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8637466B2 (en) 2008-08-11 2014-01-28 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2010105016A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
CN102421827B (zh) 2009-05-15 2014-07-30 日本化药株式会社 具有羟基的生理活性物质的高分子结合体
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
EP2493466B1 (en) 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel
EA201200617A1 (ru) * 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
US20110165155A1 (en) 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
SG183361A1 (en) 2010-02-18 2012-09-27 Ct Nac Investigaciones Oncologicas Cnio Triazolo [4, 5 - b] pyridin derivatives
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
CA2816997A1 (en) 2010-11-17 2012-05-24 Nippon Kayaku Kabushiki Kaisha Novel polymer derivative of cytidine metabolic antagonist
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
JP2014512354A (ja) 2011-04-01 2014-05-22 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びエルロチニブの組み合わせ、及び使用方法
WO2012156999A1 (en) 2011-05-19 2012-11-22 Manu Chaudhary Ready to use docetaxel formulation
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
MX349366B (es) 2011-05-19 2017-07-26 Centro Nac De Investigaciones Oncologicas (Cnio) Compuestos novedosos.
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
RS58146B1 (sr) 2011-09-08 2019-02-28 Univ New York Onkolitički herpes simpleks virus i njegova terapeutska upotreba
CA2847114C (en) 2011-09-11 2018-08-21 Nippon Kayaku Kabushiki Kaisha Method for manufacturing block copolymer
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
KR101909801B1 (ko) 2012-06-08 2018-10-18 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
WO2014014518A1 (en) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014149871A1 (en) 2013-03-14 2014-09-25 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
WO2015050844A1 (en) 2013-10-01 2015-04-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Anti-egfr antibodies and antibody drug conjugates
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP3307330B1 (en) 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CN109562169A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN109963870B (zh) 2016-06-08 2023-07-28 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CA3027046A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
WO2019047812A1 (zh) 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4507217A (en) * 1983-03-07 1985-03-26 Lipid Specialties, Inc. Magnetic compositions and magnetic memory devices prepared therefrom
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
JP2919867B2 (ja) * 1989-09-27 1999-07-19 千寿製薬株式会社 抗腫瘍剤
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液

Also Published As

Publication number Publication date
FR2698543B1 (fr) 1994-12-30
CA2150576A1 (fr) 1994-06-09
HU9501596D0 (en) 1995-08-28
DE69328192T2 (de) 2000-09-28
PT671912E (pt) 2000-06-30
SK281558B6 (sk) 2001-05-10
MX9306986A (es) 1995-01-31
NO952151L (no) 1995-05-31
ZA938936B (en) 1994-08-03
HU222833B1 (hu) 2003-11-28
EP0671912A1 (fr) 1995-09-20
EP0671912B1 (fr) 2000-03-22
FI952680L (fi) 1995-06-01
AU691476B2 (en) 1998-05-21
JPH08503689A (ja) 1996-04-23
FR2698543A1 (fr) 1994-06-03
ES2145115T4 (es) 2010-06-17
PL174334B1 (pl) 1998-07-31
CN1636560A (zh) 2005-07-13
HK1075197A1 (en) 2005-12-09
JP3689791B2 (ja) 2005-08-31
DE69328192T4 (de) 2007-07-19
YU74593A (sh) 1996-08-13
GEP19991856B (en) 1999-12-06
YU49092B (sh) 2003-12-31
ATE190838T1 (de) 2000-04-15
GR3032828T3 (en) 2000-06-30
TW271395B (cg-RX-API-DMAC7.html) 1996-03-01
NZ258150A (en) 1996-11-26
PL309197A1 (en) 1995-09-18
WO1994012171A1 (fr) 1994-06-09
AU5566994A (en) 1994-06-22
SK72595A3 (en) 1995-11-08
CZ284080B6 (cs) 1998-08-12
KR950703946A (ko) 1995-11-17
NO952151D0 (no) 1995-05-31
NO314436B1 (no) 2003-03-24
CA2150576C (fr) 2005-06-21
RU2144356C1 (ru) 2000-01-20
DK0671912T3 (da) 2000-07-03
CZ142195A3 (en) 1995-10-18
US5438072A (en) 1995-08-01
ES2145115T3 (es) 2000-07-01
FI113619B (fi) 2004-05-31
HUT72650A (en) 1996-05-28
KR100330316B1 (ko) 2002-11-04
CN1291713C (zh) 2006-12-27
FI952680A0 (fi) 1995-06-01
DE69328192D1 (de) 2000-04-27

Similar Documents

Publication Publication Date Title
CN1291713C (zh) 以塔三烷衍生物为主组分的新组合物
EP0593656B3 (fr) Nouvelles compositions a base de derives de la classe des taxanes
CN1169525C (zh) 紫杉烷的药物制剂
CN1283243C (zh) 新的以紫杉化合物为主要组分的药物组合物
US10842770B2 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CN1248680C (zh) 紫杉醇的可注射组合物
CN1655824A (zh) 基于聚氧乙烯蓖麻油的稳定药物制剂及其生产方法
EP2205215A2 (en) Docetaxel injectable composition, being absolutely free of ethanol
CN1111128A (zh) 含吡氧噻嗪的皮肤表面抗炎组合物
CN1075633A (zh) 脂质体炎痛喜康制剂
HK1075197B (en) New composition containing taxane derivatives as major component
CN1655790A (zh) 药物组合物
CN1714785A (zh) 一种含有紫杉醇类化合物的浓缩乳化剂及其使用方法
HK1081451B (en) Medicinal composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C56 Change in the name or address of the patentee

Owner name: AVENTIS PHARMA S.A.

Free format text: FORMER NAME OR ADDRESS: RHONE-POULENC RORER S.A.

CP01 Change in the name or title of a patent holder

Patentee after: Awentis Pharmaceutical S. A.

Patentee before: Rhone-Poulenc Rorer S.A.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication